Cognition Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Cognition Therapeutics, Inc. (CGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 92.29% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-03-26
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2024-03-31 was 92.29%, a 0.42% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-03-31 was 92.68%.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2021-03-31 was 101.83%.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 92.29%, a 0.42% decline from fiscal 2023.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 92.68%, a 0.05% decline from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 92.73%, a 8.94% decline from fiscal 2021.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 101.83%, a 6.87% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 92.29% 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | 92.29% 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 92.29% 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 92.29% 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | 92.68% 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | 92.68% 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | 92.68% 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 92.68% 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | 92.73% 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | 92.72% 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | 92.72% 10-Q · filed 2023-08-08 | ||||
| 2021-12-31 | 101.83% 10-K · filed 2023-03-23 | 104.79% 10-K · filed 2022-03-30 | |||
| 2021-09-30 | 101.83% 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | 101.83% 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 101.83% 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | 109.34% 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | 109.34% 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |